Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

1(33.3%)

Phase 4

1(33.3%)

Phase 2

1(33.3%)

3Total

N/A(1)

Phase 4(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials

NCT06700421Phase 2Active Not Recruiting

Phase II Clinical Study of Adebrelimab Combined with Apatinib in the Treatment of Locally Advanced Non-small Cell Lung Cancer Patients with Radiation Pneumonitis

Role: lead

NCT06587178Not ApplicableNot Yet Recruiting

Semi-elemental Versus Polymeric EEN in the Preoperative Optimization for Patients with CD

Role: lead

NCT01819961Phase 4Unknown

Parenteral Fish Oil in Major Laparoscopic Abdominal Surgery

Role: lead

All 3 trials loaded